Service
Our end-to-end Switch Program supports the seamless transition to new CELLiST™ cell culture media, reducing production costs and ensuring optimal compatibility with your biopharmaceutical processes. Our dedicated team partners with you to ensure your goals are met seamlessly and efficiently.
[Breakdown of Cost of Goods Sold (COGs)]
Our Switch Program offers exceptional cost-efficiency by reducing a major component of upstream costs, which are media expenditures. Upstream process costs account for 30-40% of total bioprocess expenses. By switching to high-performance, cost-effective media and reducing batch numbers, our Switch Program can significantly lower labor, consumable, and operational costs. Additionally, it can help reduce downstream processing costs, further enhancing operational efficiency.
Experience a hassle-free transition with our Switch Program. Our end-to-end service encompasses not only the development of optimized media but also comprehensive change control support, ensuring a smooth and efficient process throughout.
Switch Program Process
Absolutely. Our Switch Program has a proven track record of successfully optimizing cell culture processes for various projects. As demonstrated in the case study below, we leveraged media development and a Quality by Design (QbD) approach to improve the cell culture process for a client’s biosimilar pipeline. This effort contributed to the successful EMA approval of a biosimilar anti-cancer therapeutic, now advancing through commercialization.
Our program ensures smooth transitions with a focus on maintaining product quality and speeding up time-to-market.
SAMPLE